Last updated: 2026-10-13 05:03:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Pharvaris N.V. (PHVS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $30,87, with a market capitalisation of $2,18B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $20,65 to $43,25. This page covers its latest market performance, valuation, price trends and company information.
$2,18B | |
$31,09 | |
$43,25 | |
$1,77 | |
$31,10 | |
585,48K | |
720,42K | |
-- | |
$43,25 | |
$20,65 | |
-- | |
-- |
Pharvaris N.V. (PHVS) last closed at $31,10 as of 2026-10-12 23:31:00, unchanged from the previous close of $31,10.
During the latest regular trading session, PHVS traded between $1,77 and $43,25, with a volume of 585,48K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Pharvaris N.V. (PHVS) moved from $31,01 to $30,87, representing a decline of 0,45% ($0,14).
The stock traded between $30,15 and $34,31 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 652,20 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45,2%
PHVS is currently trading at $30,87, placing it 45,2% of the way from its 52-week low of $20,65 to its 52-week high of $43,25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
| Employees | 129 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pharvaris N.V. (PHVS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.